Nytamel (Zolpidem Hemitartrate)

Zolpidem Hemitartrate, the active ingredient in Nytmel, is an imidazopyridine presented as a tablet for oral use. It is indicated for the short‑term management of insomnia in adults. GNH USA supplies Nytmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Nytmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Nytmel is used in the management of sleep‑related disorders, acting on central nervous system pathways that regulate sleep onset.

- Insomnia: helps patients fall asleep more quickly and maintain sleep through the night. - Transient sleep disturbance: reduces nighttime awakenings for short‑term relief. - Pre‑procedural anxiety related to sleep: provides a calming effect to facilitate rest before minor procedures.

Adverse reactions to Nytmel vary in frequency and severity.

Common Side Effects: - Drowsiness or excessive daytime sleepiness - Dizziness - Headache - Nausea - Dry mouth - Unpleasant taste

Serious or Rare Side Effects: - Complex sleep‑related behaviours (e.g., sleep‑walking, driving while asleep) - Allergic reactions such as rash, itching or swelling - Mood changes including depression or suicidal thoughts - Respiratory depression in susceptible individuals - Hallucinations or delusional states

When prescribing Nytmel, clinicians should consider several safety aspects.

- Assess sleep disorder duration: limit use to short‑term therapy (typically ≤4 weeks). - Evaluate hepatic function: dose adjustment may be needed in severe liver impairment. - Review concomitant CNS depressants: avoid additive sedation. - Advise patients on next‑day activity: caution with driving or operating machinery. - Monitor for complex sleep behaviours: discontinue if observed. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nytmel may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – increased zolpidem exposure. - Opioids or other central nervous system depressants – heightened risk of respiratory depression. - Alcohol: additive sedative effects and impaired cognition.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates (e.g., warfarin) – potential alteration in plasma levels. - Antidepressants that affect serotonin reuptake – may increase risk of serotonin syndrome. - Antihistamines with sedating properties – enhanced drowsiness.